2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Why the study?
Cardiovascular complications in patients with cancer receiving anticancer treatments and survivors require comprehensive risk stratification, monitoring, prevention, and management strategies.
Key Points
- Cardiac implantable electronic devices are critical in managing cardiovascular complications.
- Patients aged 65-74 years and those with chronic myeloid leukaemia face unique cardiac risks.
- Guidelines include advanced cardiac magnetic resonance techniques for better diagnosis and management of cardiac issues in cancer patients. Their implementation may improve patient outcomes during cancer treatment.
Structured PICO
P
Population
Patients with cancer receiving anticancer treatments and cancer survivors at risk for or experiencing cardiovascular complications
I
Intervention
Cardiovascular risk stratification, monitoring, prevention, and management strategies (cardio-oncology care)
The 2022 ESC Guidelines provide comprehensive recommendations for the cardiovascular management of patients receiving anticancer treatments and cancer survivors.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We're doing a lot of surveillance because one of the big advantages of cardio-oncology is we know when someone is about to get treated. You don't know in nature when someone's going to have an acute myocardial infarction or acute viral myocarditis, but we do know when they're coming into an oncology clinic to get an infusion of chemotherapy or tablets.”
“Guidelines are living documents, and they're meant to be dynamic and updated over time according to the evidence. So, in that sense, it is important to be able to have a healthy dialogue and discourse about them within the community.”
“This is an authoritative document, and it covers a tremendous amount of territory.”
Implication
Standardizes cardio-oncology care for clinicians; extends prior consensus into the first dedicated guideline framework.
Abstract
65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR Cardiac magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Lyon et al. (2022) conducted a review in Cancer therapy-related cardiovascular toxicity. The 2022 ESC Guidelines provide comprehensive recommendations for the prevention, diagnosis, and management of cardiovascular toxicity related to cancer therapies.